Introduction
Inhibition of CCKA
Application of CCK-AR antagonists can offset the reduction in food intake and satiety caused by a high-fat diet. Intravenous injection of the CCKA receptor antagonist loxiglumide can significantly reduce dietary satiety and nausea and reduce the pressure during bloating. The use of the CCK-AR antagonist loxiglumide increases insulin secretion without changing the original sugar intake and eliminates all pathways for postprandial secretion of the pancreatic polypeptide. Dexloxiglumide is a right-handed body of loxiglumide. It is a potent and selective CCK1 receptor antagonist for the treatment of constipation-type irritable bowel syndrome. It is the most advanced CCK1 in clinical gastroenterology research. A body antagonist is a CCK1 receptor antagonist with a variety of pharmacological activities. CCKA receptor antagonists have been widely recognized for increased food intake. Administration of CCK-AR agonists and antagonists, respectively, can enhance or inhibit pancreatic hyperplasia.
CCKA and diseases
Overexpression of neuropeptide Y (NPY) occurs when CCK-AR is absent, leading to uncontrolled eating and obesity. CCK-AR and CCK-BR mutations exist in diabetic and obese people. V3651CCK-AR mutation reduces the expression of CCK-AR and the stimulation of phosphoinositide, which leads to a decrease in feeding regulation. Moreover, CCK1R can reduce the migration of cancer cells in cancer cell lines.
Application of CCK-AR antagonists can offset the reduction in food intake and satiety caused by a high-fat diet. Intravenous injection of the CCKA receptor antagonist loxiglumide can significantly reduce dietary satiety and nausea and reduce the pressure during bloating. The use of the CCK-AR antagonist loxiglumide increases insulin secretion without changing the original sugar intake and eliminates all pathways for postprandial secretion of the pancreatic polypeptide. Dexloxiglumide is a right-handed body of loxiglumide. It is a potent and selective CCK1 receptor antagonist for the treatment of constipation-type irritable bowel syndrome. It is the most advanced CCK1 in clinical gastroenterology research. A body antagonist is a CCK1 receptor antagonist with a variety of pharmacological activities. CCKA receptor antagonists have been widely recognized for increased food intake. Administration of CCK-AR agonists and antagonists, respectively, can enhance or inhibit pancreatic hyperplasia.
CCKA and diseases
Overexpression of neuropeptide Y (NPY) occurs when CCK-AR is absent, leading to uncontrolled eating and obesity. CCK-AR and CCK-BR mutations exist in diabetic and obese people. V3651CCK-AR mutation reduces the expression of CCK-AR and the stimulation of phosphoinositide, which leads to a decrease in feeding regulation. Moreover, CCK1R can reduce the migration of cancer cells in cancer cell lines.
Contact Info
Address:
45-16 Ramsey Road, Shirley, NY 11967, USA
Shirley, NY
New York 11967
United States
Shirley, NY
New York 11967
United States
Tel:
Website:
https://www.bocsci.com/tag/cholecystokinin-a-ccka-396.html
Hours of operation
| From | To | From | To | From | To | ||
|---|---|---|---|---|---|---|---|
| Monday | Open | ||||||
| Tuesday | Open | ||||||
| Wednesday | Open | ||||||
| Thursday | Open | ||||||
| Friday | Open | ||||||
| Saturday | Open | ||||||
| Sunday | Open | ||||||
